Brought to you by 
Dainippon Sumitomo to buy Sepracor for $2.55bn
05 Feb 2021
Executive Summary
In a deal valued at about $2.55bn, Dainippon Sumitomo Pharma (DSP; Japan's seventh-largest drug company in terms of sales) agreed to pay $23 (a 26% premium) for each of US biotech Sepracor's 111mm outstanding shares.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Chiral Chemistry
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dainippon Sumitomo to buy Sepracor for $2.55bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice